At the 2010 Gastrointestinal Cancers Symposium, new data from the CRYSTAL trial identified BRAF gene mutations as a poor prognostic indicator in metastatic colorectal cancer (mCRC) but not predictive of response to therapy.
By Christin Melton
Advertisement
Articles by By Christin Melton
Advertisement
Latest Updated Articles
- Updated CRYSTAL Data Support Effectiveness of Cetuximab (Erbitux) in Wild-Type KRAS Metastatic Colorectal Cancer
Published: May 19th 2010 | Updated:
Advertisement
Advertisement
Trending on CGTlive®
1
Tr1X's Multiple Sclerosis Cell Therapy TRX319 Cleared for US Trial
2
Krystal Biotech’s Neurotrophic Keratitis Gene Therapy Viral Vector Secures FDA Platform Technology Designation
3
Around the Helix: Cell and Gene Therapy Company Updates – October 15, 2025
4
FDA Picks Abeona’s XLRS Gene Therapy ABO-503 for RDEA Pilot Program
5
